Apixaban, an oral, direct inhibitor of activated Factor Xa.
作者信息
Shantsila Eduard, Lip Gregory Y H
机构信息
City Hospital, University Department of Medicine, Haemostasis Thrombosis and Vascular Biology Unit, Dudley Road, Birmingham, B18 7QH, UK.
出版信息
Curr Opin Investig Drugs. 2008 Sep;9(9):1020-33.
PMID:18729009
Abstract
Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for cerebrovascular ischemia, deep vein thrombosis and lung embolism, and phase II clinical trials for coronary artery disease.
摘要
Zotero 插件